Whalen Wealth Management Inc. Takes $264,000 Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Whalen Wealth Management Inc. bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 1,933 shares of the company’s stock, valued at approximately $264,000.

Several other large investors also recently bought and sold shares of the stock. Dimensional Fund Advisors LP grew its position in shares of Neurocrine Biosciences by 45.5% during the second quarter. Dimensional Fund Advisors LP now owns 472,929 shares of the company’s stock worth $65,097,000 after buying an additional 147,907 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in Neurocrine Biosciences by 5.6% in the second quarter. Mercer Global Advisors Inc. ADV now owns 8,123 shares of the company’s stock worth $1,118,000 after acquiring an additional 430 shares during the last quarter. Pacer Advisors Inc. grew its holdings in Neurocrine Biosciences by 76.1% during the 2nd quarter. Pacer Advisors Inc. now owns 31,890 shares of the company’s stock worth $4,390,000 after acquiring an additional 13,782 shares in the last quarter. Sei Investments Co. grew its holdings in Neurocrine Biosciences by 47.7% during the 2nd quarter. Sei Investments Co. now owns 128,016 shares of the company’s stock worth $17,624,000 after acquiring an additional 41,347 shares in the last quarter. Finally, Thrivent Financial for Lutherans increased its position in shares of Neurocrine Biosciences by 86.8% in the 2nd quarter. Thrivent Financial for Lutherans now owns 46,577 shares of the company’s stock valued at $6,412,000 after purchasing an additional 21,641 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Analyst Ratings Changes

NBIX has been the subject of several recent analyst reports. BMO Capital Markets decreased their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. Raymond James reaffirmed an “outperform” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. UBS Group raised their target price on Neurocrine Biosciences from $142.00 to $162.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Royal Bank of Canada lowered their price target on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a report on Friday, October 4th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a report on Friday, December 20th. Five investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $164.81.

Insider Buying and Selling at Neurocrine Biosciences

In other news, insider Jude Onyia sold 2,331 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the sale, the insider now directly owns 15,449 shares of the company’s stock, valued at $1,951,054.21. This trade represents a 13.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kyle Gano sold 65,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total value of $9,197,500.00. Following the transaction, the chief executive officer now directly owns 135,392 shares in the company, valued at $19,157,968. This represents a 32.44 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 68,694 shares of company stock valued at $9,676,730. 4.30% of the stock is owned by company insiders.

Neurocrine Biosciences Trading Up 0.6 %

NASDAQ:NBIX opened at $146.76 on Thursday. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98. The stock’s 50 day simple moving average is $132.54 and its 200-day simple moving average is $131.19. The firm has a market cap of $14.86 billion, a P/E ratio of 39.35 and a beta of 0.33.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.